Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alissa Visram

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
The Lancet. Haematology|January 5, 2025
Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myelomaAlissa Visram, Hira Mian
Current Hematologic Malignancy Reports|November 23, 2022
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple MyelomaArleigh McCurdy, Alissa Visram
Blood|February 27, 2025
Hypercalcemia in MGUS: keep the differential diagnosis broadHira Mian, Alissa Visram
Clinical Liver Disease|May 2, 2019
Defining and grading HBV reactivationAlissa Visram, Jordan J Feld
Cancer Treatment and Research Communications|November 27, 2021
Aging-associated immune system changes in multiple myeloma: The dark side of the moonAlissa Visram, Taxiarchis V Kourelis
Hematology. American Society of Hematology. Education Program|December 10, 2021
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategiesAlissa Visram, Joselle Cook, Rahma Warsame
Presse Medicale (Paris, France : 1983)|December 14, 2024
Treatment of elderly and frail myeloma patientsSteven Chun-Min Shih, Alissa Visram, Hira Mian
Advances in Clinical Chemistry|February 25, 2019
Laboratory assessment of multiple myelomaTracy Morrison, Ronald A Booth, Kristin Hauff, et al.
Blood Cancer Journal|March 2, 2021
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppressionAlissa Visram, Surendra Dasari, Emilie Anderson, et al.
Leukemia Research|September 3, 2020
Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studiesHarinad Maganti, Alissa Visram, Risa Shorr, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
The Lancet. Haematology|January 5, 2025
Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myelomaAlissa Visram, Hira Mian
Current Hematologic Malignancy Reports|November 23, 2022
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple MyelomaArleigh McCurdy, Alissa Visram
Blood|February 27, 2025
Hypercalcemia in MGUS: keep the differential diagnosis broadHira Mian, Alissa Visram
Clinical Liver Disease|May 2, 2019
Defining and grading HBV reactivationAlissa Visram, Jordan J Feld
Cancer Treatment and Research Communications|November 27, 2021
Aging-associated immune system changes in multiple myeloma: The dark side of the moonAlissa Visram, Taxiarchis V Kourelis
Hematology. American Society of Hematology. Education Program|December 10, 2021
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategiesAlissa Visram, Joselle Cook, Rahma Warsame
Presse Medicale (Paris, France : 1983)|December 14, 2024
Treatment of elderly and frail myeloma patientsSteven Chun-Min Shih, Alissa Visram, Hira Mian
Advances in Clinical Chemistry|February 25, 2019
Laboratory assessment of multiple myelomaTracy Morrison, Ronald A Booth, Kristin Hauff, et al.
Blood Cancer Journal|March 2, 2021
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppressionAlissa Visram, Surendra Dasari, Emilie Anderson, et al.
Leukemia Research|September 3, 2020
Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studiesHarinad Maganti, Alissa Visram, Risa Shorr, et al.
Pageof 8